Freeline Therapeutics Holdings plc logo

Freeline Therapeutics Holdings plc

NASDAQ:FRLN

Overview | Financials
Company Name Freeline Therapeutics Holdings plc
Symbol FRLN
Currency USD
Price 6.49
Market Cap 28,283,096
Dividend Yield 0%
52-week-range 2.11 - 8.745
Industry Biotechnology
Sector Healthcare
CEO Mr. Michael J. Parini J.D.
Website https://www.freeline.life

An error occurred while fetching data.

About Freeline Therapeutics Holdings plc

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment

Related Stocks

BioSig Technologies, Inc. logo

BioSig Technologies, Inc.

BSGM

0.31 USD

Sera Prognostics, Inc. logo

Sera Prognostics, Inc.

SERA

7.71 USD

BeyondSpring Inc. logo

BeyondSpring Inc.

BYSI

2.39 USD

OKYO Pharma Limited logo

OKYO Pharma Limited

OKYO

1.01 USD

ProQR Therapeutics N.V. logo

ProQR Therapeutics N.V.

PRQR

4.49 USD

MiNK Therapeutics, Inc. logo

MiNK Therapeutics, Inc.

INKT

0.67 USD

Financials

Numbers are in millions USD

Numbers are in millions USD